rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM

Diabetes

Volumn 46, Issue 9, 1997, Pages 1453-1458

  Carroll, Paul V ^a   Umpleby, Margot ^a   Ward, Gill S ^a   Imuere, Stephen ^a   Alexander, Elaine ^c   Dunger, David ^b   Sönksen, Peter H ^a   Russell Jones, David L ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030821277     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.9.1453     Document Type: Article

References (41)

1. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253:2769-2776, 1978
2. Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB, Shojaee-Moradie FS, Hopkins KD, Jackson NJ, Kelly JM, Jones RH, Sönksen PH: Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Physiol 267:E591-E598, 1994
3. Zenobi PD, Graf S, Ursprung H, Froesch ER: Effects of insulin-like growth factor-I on glucose tolerance, insulin levels and insulin secretion in healthy man. J Clin Invest 89:1908-1913, 1992
4. Cotterill AM: The therapeutic potential of recombinant human insulin-like growth factor I. Clin Endocrinol 37:11-16, 1992
5. Mauras N, Horber FF, Haymond MW: Low dose recombinant human insulin-like growth factor I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 75:1192-1197, 1992
6. Bach MA, Chin E, Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:1040-1045, 1994
7. Dunger DB, Cheetham TD, Crowne EC: Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metab Clin Exp 44 (Suppl. 4):119-123, 1995
8. Amiel SA, Sherwin RS, Hintz R, Gertner JM, Press CM, Tamborlane WV: Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 33:1175-1179, 1984
9. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER: Insulin regulates insulin-like growth factor-I mRNA in rat hepatocytes. Am J Physiol 260:E846-E851, 1991
10. Wurzburger MI, Prelevic GM, Sönksen PH, Wheeler M, Balint-Peric L: Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32:131-134, 1995
11. Russell-Jones DL, Rattray M, Wilson VJ, Jones RH, Sönksen PH, Thomas CR: Intraperitoneal insulin is more potent than subcutaneous insulin at restoring hepatic insulin-like growth factor-I mRNA levels in the diabetic rat a functional role for the portal vascular link. J Mol Endocrinol 9:257-263, 1992
12. Griffen SC, Russell SM, Katz LS, Nicoll CS: Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver. Proc Natl Acad Sci USA 84:7300-7304, 1987
13. Sönksen PH, Russell-Jones DL, Jones RH: Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68-79, 1993
14. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP: Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1362, 1990
15. Fowelin J, Attvall S, von Schenk H, Smith U, Lager I: Characterisation of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34:500-506, 1991
16. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type I (insulin-dependant) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52-59, 1990
17. Merimee TJ: Diabetic retinopathy: a synthesis of perspectives. N Engl J Med 322:978-983, 1990
18. Cheetham T, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB: The effects of recombinant insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin-dependant) diabetes mellitus. Diabetologia 36:678-681, 1993
19. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type II diabetes mellitus. J Clin Invest 90:2234-2241, 1993
20. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmamm M, Froesch ER: Recombinant human insulin-like growth factor-I (rhIGF-I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 34:675-679, 1991
21. Zenobi PD, Graf S, Thut A, Riesen W, Froesch ER: Effects of recombinant human insulin-like growth factor-I (rhIGF-I) infusions on glucose and lipid metabolism in healthy man (Abstract). In Proceedings of the 2nd International Meeting on Somatomedins/IGFs, San Francisco D4, 1991.
22. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS: Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat: comparison with insulin. J Clin Invest 83:1717-1723, 1989
23. Leahy JL, Vandekerkhove KM: Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126:1593-1598, 1990
24. Friede wald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
25. Sönksen PH: Double antibody technique for the simultaneous assay of insulin and growth hormone. In Hormones in Human Blood: Detection Assay. Antoniades H, Ed. Cambridge, MA, Harvard University Press, 1976
26. Dauncey MJ, Murgatroyd Pr, Cole TJ: A calorimeter for the direct and indirect measurement of 24 h energy expenditure. Br J Nutr 39:557-566, 1978
27. Matthews DR: Time series analysis in endocrinology. Acta Paediatr Scand 347 (Suppl.):55-62, 1988
28. Clemmons DR, Smith-Banks A, Underwood LE: Reversal of diet-induced catabolism by infusion of recombinant IGF-I in humans. J Clin Endocrinol Metab 75:234-238, 1992
29. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP: Adverse effects of recombinant human insulin-like growth factor-I in obese insulin-resistant type II diabetic patients. Diabetes 43:369-374, 1994
30. Bermann M, Jaffe CA, Tsai W, DeMott-Friberg R, Barkan Al: Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor-I: involvement of hypothalamic somatostatin. J Clin Invest 94:138-145, 1994
31. Rymaszewski Z, Cohen RM, Chomczynski P: Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA 88:617-621, 1991
32. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140, 1987
33. Ferrannini E, Haffner SM, Michell BD, Stern MP: Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416-422, 1991
34. Fontbonne AM, Eschwège EM: Insulin and cardiovascular disease: Paris prospective study. Diabetes Care 14:461-469, 1991
35. Grant MB, Guay C, Marsh R: Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal epithelial cells. Curr Eye Res 9:323-335, 1990
36. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ: Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307-313, 1991
37. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER: Insulin-like growth factor-I stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 95:2249-2256, 1993
38. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER: Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone deficient humans. J Clin Invest 94:1126-1133, 1994
39. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS: Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 262:E130-E133, 1992
40. Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, Jackson N, Kelly J, Shojaee-Moradie F, Jones RH, Sönksen PH: A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 25:403-411, 1995
41. Raben MS, Hollenberg CH: Effect of growth hormone on plasma fatty acids. J Clin Invest 38:484, 1959